Is Pfizer-Allergan the End of Tax Inversion Deals?

The transcript discusses the US government's targeting of the Pfizer-Allergan merger through new regulations, impacting the future of corporate inversions. It highlights the financial consequences for investment banks involved in such deals, particularly smaller firms like Mollis. The discussion also covers the anticipation of regulatory changes by the companies involved and the relatively small breakup fees. Finally, it examines the stock market reactions and strategic implications for Pfizer and Allergan following the failed merger.

What were the implications of the new regulations targeting Pfizer and Allergan?

How did the failure of the merger affect the involved banks and their advisory fees?

What factors contributed to the perception that the new rules were a low probability event?

What were the market reactions of Pfizer and Allergan after the merger announcement?

Discuss the potential future strategies for Allergan following the failed merger.